Drugs / gp100:154-162 peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00923195 | Dec 2008 → Aug 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100:154-162 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923195 ↗ |
| Action | Activate | “The procedure also uses one of two vaccines-the anti-MART-1 peptide or the anti-gp100 peptide-to stimulate cells in the immune system” NCT00923195 ↗ |
| Route | Subcutaneous | “One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh” NCT00923195 ↗ |